With this purpose, in our study we evaluated expression of CD34, CD68, CD163, CD3, CD8 and PD-L1 in patients with CHL, comparing the data between the groups of responders (RESP) and non-responders patients (RESP) to first-line treatment constituted by ABVD treatment [25]. Here, CD274 is linked to classic Hodgkin lymphoma.